Astrazeneca Plc $AZN Shares Acquired by Integral Health Asset Management LLC

Key Points

• Integral Health Asset Management increased its stake in AstraZeneca by 50% in Q3, buying 100,000 shares to hold 300,000 shares valued at about $23.02 million, representing roughly 1.6% of the fund and its 15th largest position.
• AstraZeneca declared a dividend of $1.595 per share with a record date of February 20 and a payment date of March 23 (ex-dividend date February 20).
• Analysts maintain a consensus rating of "Moderate Buy" (nine Buys, one Sell) with an average price target of $95.75; the stock was trading near $190.20 with a market cap of about $295 billion and a P/E of 29.04.

Integral Health Asset Management LLC increased its holdings in shares of Astrazeneca Plc (NYSE:AZN - Free Report) by 50.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 300,000 shares of the company's stock after purchasing an additional 100,000 shares during the quarter. Astrazeneca makes up approximately 1.6% of Integral Health Asset Management LLC's portfolio, making the stock its 15th biggest position. Integral Health Asset Management LLC's holdings in Astrazeneca were worth $23,016,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Rakuten Investment Management Inc. acquired a new stake in Astrazeneca during the third quarter worth approximately $31,000. FSA Wealth Management LLC boosted its holdings in shares of Astrazeneca by 376.0% in the 2nd quarter. FSA Wealth Management LLC now owns 476 shares of the company's stock valued at $33,000 after buying an additional 376 shares in the last quarter. VSM Wealth Advisory LLC acquired a new position in shares of Astrazeneca in the 2nd quarter valued at $33,000. E Fund Management Hong Kong Co. Ltd. grew its position in shares of Astrazeneca by 144.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company's stock valued at $36,000 after buying an additional 275 shares during the last quarter. Finally, Abound Wealth Management grew its position in shares of Astrazeneca by 1,767.9% in the 3rd quarter. Abound Wealth Management now owns 523 shares of the company's stock valued at $40,000 after buying an additional 495 shares during the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on AZN shares. Wall Street Zen cut shares of Astrazeneca from a "buy" rating to a "hold" rating in a research report on Thursday. HSBC reaffirmed a "buy" rating and set a $108.00 price objective on shares of Astrazeneca in a report on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft reiterated a "sell" rating on shares of Astrazeneca in a research report on Friday, February 6th. Guggenheim reissued a "buy" rating on shares of Astrazeneca in a research report on Wednesday, December 3rd. Finally, TD Cowen restated a "buy" rating on shares of Astrazeneca in a research note on Tuesday, December 9th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Astrazeneca presently has a consensus rating of "Moderate Buy" and an average price target of $95.75.

Astrazeneca Trading Down 1.2%

NYSE:AZN opened at $190.20 on Friday. Astrazeneca Plc has a 1 year low of $122.48 and a 1 year high of $212.71. The company has a debt-to-equity ratio of 0.51, a current ratio of 0.94 and a quick ratio of 0.72. The firm has a market capitalization of $294.98 billion, a price-to-earnings ratio of 29.04, a price-to-earnings-growth ratio of 1.45 and a beta of 0.32.

Astrazeneca Announces Dividend

The business also recently declared a dividend, which will be paid on Monday, March 23rd. Stockholders of record on Friday, February 20th will be given a dividend of $1.595 per share. This represents a dividend yield of 156.0%. The ex-dividend date is Friday, February 20th. Astrazeneca's dividend payout ratio (DPR) is presently 66.26%.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.